Phosphorothioate oligonucleotides derived from human immunodeficiency virus type 1 (HIV-1) primer tRNA(Lys3) are strong inhibitors of HIV-1 reverse transcriptase and arrest viral replication in infected cells

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2141-2148

  El Dirani Diab, Rim ^a,b   Sarih Cottin, Leila ^a,b   Delord, Brigitte ^a,c   Dumon, Béatrice ^a,c   Moreau, Serge ^a,d   Toulme, Jean Jacques ^a,d   Fleury, Hervé ^a,c   Litvak, Simon ^a,b  

^a Inst Federatif Rech Pathologies I   (France)

^b Institut de Biochimie et Genetique Cellulaires   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; PRIMER RNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSFER RNA;

ARTICLE; BINDING AFFINITY; CELL FREE SYSTEM; DRUG MECHANISM; ENZYME BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0030850944     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2141     Document Type: Article

References (46)

1. Agrawal, S. 1991. Antisense oligonucleotides: possible approaches for chemotherapy of AIDS, p. 143-159. In E. Wickstrom (ed.), Prospects for antisense nucleic acid therapy of cancer and AIDS. Liss, New York, N.Y.
2. Agrawal, S., and J. Lisziewicz. 1994. Potential for HIV-1 treatment with antisense oligonucleotides. J. Biotechnol. Healthcare 1:167-182.
3. Alizon, M., S. Wain-Hobson, L. Montagnier, and P. Sonigo. 1986. Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell 46:63-74.
4. Lys with the p66/p66 form of HIV-1 reverse transcriptase stimulates DNA polymerase and ribonuclease H activities. J. Biol. Chem. 267:19356-19362.
5. Aposhian, H. V., and A. Kornberg. 1962. Enzymatic synthesis of DNA. The polymerase formed after T2 bacteriophage infection of E. coli: a new enzyme. J. Biol. Chem. 237:519-526.
6. Lys3. Biochem. Biophys. Res. Commun. 225:839-843.
7. Arts, E. A., and M. A. Wainberg. 1996. Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Adv. Virus Res. 46:97-163.
8. Azad, R. F., V. Brown-Driver, R. W. Buckheit, and K. P. Anderson. 1995. Antiviral activity of phosphorothioate oligonucleotides complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antivir. Res. 28:101-111.
9. Barat, C., V. Lullien, O. Schatz, G. Keith, M. T. Nugeyre, F. Grüninger-Leitch, F. Barré-Sinoussi, S. F. J. Le Grice, and J. L. Darlix. 1989. HIV-1 reverse transcriptase specifically interacts with the anticodon domain of its cognate primer tRNA. EMBO J. 8:3279-3285.
10. Lys3 with nucleocapsid protein and reverse transcriptase. J. Mol. Biol. 231:185-190.
11. Barr, P. J., C. T. Power, H. L. Gibson, and P. A. Luciw. 1987. Expression of active HIV reverse transcriptase in Saccharomyces cerevisiae. Bio/Technology 5:486-489.
12. Boiziau, C., F. Debart, B. Rayner, J.-L. Imbach, and J.-J. Toulmé. 1995. Chimeric α-β oligonucleotides as antisense inhibitors of reverse transcription. FEBS Lett. 361:41-45.
13. Boiziau, C., L. Tarrago-Litvak, N. D. Sinha, S. Moreau, S. Litvak, and J.-J. Toulmé. 1996. Antisense oligonucleotides inhibit in vitro cDNA synthesis by HIV-1 reverse transcriptase. Antisense Nucleic Acid Drug Dev. 6:103-109.
14. Boiziau, C., N. T. Thuong, and J.-J. Toulmé. 1992. Mechanism of inhibition of reverse transcription by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 89:768-772.
15. Bordier, B., C. Hélène, P. J. Barr, S. Litvak, and L. Sarih-Cottin. 1992. In vitro effect of antisense oligonucleotides on HIV-1 reverse transcription. Nucleic Acids Res. 20:5999-6006.
16. Bordier, B., M. Peräla-Heape, G. Degols, B. Lebleu, S. Litvak, L. Sarih-Cottin, and C. Hélène. 1995. Sequence-specific inhibition of HIV reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV-infected cells. Proc. Natl. Acad. Sci. USA 92:9383-9387.
17. Brown, D. A., S.-H. Khang, S. M. Gryaznov, L. DeDionisio, O. Heideinreich, S. Sullivan, X. Xu, and M. L. Nerenberg. 1994. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269:26801-26805.
18. Darlix, J. L., M. Lapadat-Tapolsky, H. De Rocquigny, and B. P. Roques. 1995. First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. J. Mol. Biol. 254:523-537.
19. Idriss, H., and A. K. Stammers. 1994. Inhibition of HIV-1 RT by defined template-primer DNA oligonucleotides: effect of template length and binding characteristics. J. Enzyme Inhibition 8:97-112.
20. Lys3 (template/primer) complex. J. Mol. Biol. 247:236-250.
21. Lys3 modulate primer/template loop-loop interaction in the initiation complex of HIV-1 reverse transcription. J. Biol. Chem. 268:25269-25272.
22. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science 246: 1155-1158.
23. Lisziewicz, J., D. Sun, V. Metelev, P. Zamecnik, R. C. Gallo, and S. Agrawal. 1993. Long-term treatment of HIV-infected cells with antisense oligonucleotide phosphorothioates. Proc. Natl. Acad. Sci. USA 90:3860-3864.
24. Lisziewicz, J., D. Sun, F. F. Weichold, A. R. Thierry, P. Lusso, J. Tang, R. C. Gallo, and S. Agrawal. 1994. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of HIV-1 in human peripheral blood cells. Proc. Natl. Acad. Sci. USA 91:7942-7946.
25. Litvak, S. 1996. Retroviral reverse transcriptases. RG Landes/Chapman & Hall, Austin, Tex.
26. Lys3: role of reverse transcriptase. Trends Biochem. Sci. 19:114-118.
27. Lys into HIV-1 particles. J. Virol. 68:2065-2072.
28. Marshall, M. S., and M. H. Caruthers. 1993. Phosphorodithioate DNA as a potential therapeutic drug. Science 259:1564-1570.
29. Lys3 to reverse transcriptase from HIV-1. EMBO J. 14:2679-2687.
30. Lys3 to reverse transcriptase of the HIV-1. J. Biol. Chem. 270:23867-23874.
31. Pauwels, R., J. Balzarini, and M. Baba. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV-compounds. J. Virol. Methods 20:309-321.
32. Lys from rabbit liver and SV40-transformed mouse fibroblasts. Eur. J. Biochem. 97:305-318.
33. Ramazeilles, C., R. K. Mishra, S. Moreau, E. Pascolo, and J.-J. Toulmé. 1994. Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis. Proc. Natl. Acad. Sci. USA 91:7859-7863.
34. Reed, L. J., and H. A. Muench. 1938. A simple method of estimating fifty percent of end points. Am. J. Hyg. 27:493-497.
35. Lys induce important structural changes in HIV reverse transcriptase. FEBS Lett. 277:239-242.
36. Sallafranque-Andréola, M., D. Robert, P. J. Barr, M. Fournier, S. Litvak, L. Sarih-Cottin, and L. Tarrago-Litvak. 1989. HIV-1 reverse transcriptase expressed in transformed yeast cells. Eur. J. Biochem. 184:367-374.
37. Lys as evidenced by footprinting studies and inhibition with synthetic oligoribonucleotides. J. Mol. Biol. 226:1-6.
38. Schwartz, O., Y. Henin, V. Maréchal, and L. Montagnier. 1988. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res. Hum. Retroviruses 4:441-448.
39. Skalka, A. M., and S. P. Goff. 1993. Reverse transcriptase. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
40. Stein, C. A., A. M. Cleary, L. Yakubov, and S. Lederman. 1993. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of HIV-1 gp 120. Antisense Res. Dev. 3:19-31.
41. Stein, C. A., L. M. Neckers, B. C. Nair, S. Mumbauer, G. Hoke, and R. Pal. 1991. Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. J. Acquired Immune Defic. Syndr. 4:686-693.
42. Tanaka, H., P. Vickart, J.-R. Bertrand, B. Rayner, F. Morvan, J.-L. Imbach, D. Paulin, and C. Malvy. 1994. Sequence-specific interaction of α β-anomeric double-stranded DNA with the p50 subunit of NFκB: application to the decoy approach. Nucleic Acids Res. 22:3069-3074.
43. Tarrago-Litvak, L., M.-L. Andréola, G. A. Nevinsky, L. Sarith-Cottin, and S. Litvak. 1994. The reverse transcriptase of HIV-1: from enzymology to therapeutic intervention. FASEB J. 8:497-503.
44. Thrall, S. H., J. Reinstein, B. M. Wörhl, and R. S. Goody. 1996. Evaluation of HIV-1 reverse transcriptase primer binding tRNA binding by fluorescence spectroscopy: specificity and comparison to primer/template binding. Biochemistry 35:4609-4618.
45. Wain-Hobson, S., J. P. Vartanian, M. Henry, O. Danos, S. Cole, and M. Alizon. 1985. Nucleotide sequence of the AIDS virus, LAV. Cell 40:9-17.
46. Lys3 complexes. J. Biol. Chem. 268:13617-13624.